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Candida parapsilosis is the most frequent cause of catheter-related candidemia among
non-Candida albicans species. This may be related to intrinsic capabilities as adhering
and forming a biofilm on abiotic surfaces such as on medical devices. As previously
demonstrated, patients infected with high biofilm-producing C. parapsilosis isolates
had a greater mortality risk compared to patients infected with low biofilm-producing
C. parapsilosis isolates. We developed the BIOF–HILO assay, a MALDI–TOF mass
spectrometry (MS)-based assay, which compares mass spectra obtained from attached
and suspended isolate cells during the early (i.e., 3-h) adhesion phase of in vitro biofilm
formation. The composite correlation index (CCI) analysis was used to discriminate
between mass spectra differences of the two cell types, classifying all 50 C. parapsilosis
clinical isolates, included in the study, after only 3-h of testing, in high or low biofilm
producers. All high (n = 25) or low (n = 25) biofilm producers had, according to CCI mass
spectra comparison values, higher or lower than one CCI ratios, which were obtained by
dividing the CCIsuspendedcells by the CCIattachedcells. In conclusion, the BIOF–HILO assay
allows a rapid categorization of C. parapsilosis clinical isolates in high or low biofilm
producers. This information, if timely provided to physicians, may improve treatment
outcomes in patients with C. parapsilosis candidemia.
Keywords: MALDI-based assay, Candida parapsilosis, biofilm formation, candidemia, composite correlation
index
INTRODUCTION
Candida species are able to adhere and form a biofilm on abiotic surfaces, such as on indwelling
medical devices (e.g., vascular or urinary catheters), prosthetic heart valves, and joint replacements.
This ability may be responsible for the high mortality attributed to Candida infections in healthcare
settings (Tumbarello et al., 2007; Rajendran et al., 2016). Key factors favoring colonization and/or
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infection by biofilm-forming Candida species include high
biofilm cell concentration, altered expression of cell ergosterol
biosynthesis genes, and extracellular polymeric substances in
the biofilm matrix (Finkel and Mitchell, 2011; Taff et al., 2013;
Zarnowski et al., 2016). Notably, sessile and planktonic cells
within Candida biofilms are different in their antifungal drug
susceptibility profiles (Ramage et al., 2012), because biofilm
growth would prompt the sessile cells to acquire a reduced
susceptibility against antifungal agents (Silva et al., 2017).
During the last decade, Candida parapsilosis or Candida
glabrata are on first and second position of non-Candida
albicans Candida (NCAC) species isolated from patients
with symptomatic bloodstream infection causing increased
candidemia incidence (Guinea, 2014). C. parapsilosis exhibits
the highest capability of adhering to abiotic surfaces among
NCAC species (including Candida tropicalis) (Cavalheiro and
Teixeira, 2018) and, consequently, this species is considered
the most causative agent for catheter-related infections (Bouza
et al., 2014). High (and/or moderate) biofilm formation levels
were a significant risk factor for in-hospital mortality in
C. parapsilosis candidemia (Soldini et al., 2018). Therefore, rapid
information on high or low biofilm-forming C. parapsilosis
isolates would aid to improve treatment outcomes in infected
patients (Sanguinetti and Posteraro, 2016).
High or low biofilm-producing C. parapsilosis isolates differ
regarding attached or suspended cells in the early in vitro
adhesion phase of biofilm formation (Pannanusorn et al., 2014).
This difference is beneficial to discriminate between the two
isolate types after their 3-h adhesion. With this in mind, we
developed the BIOF–HILO assay, which uses MALDI–TOF
mass spectrometry (MS) technology coupled with the composite
correlation index (CCI) analysis of protein profiles, allowing a
rapid (i.e., 3-h) identification of high- or low-biofilm-forming
C. parapsilosis isolates. Specifically, we performed a quantitative
comparison of the mass spectra obtained from attached and
suspended C. parapsilosis isolates’ cells during the initial in vitro
biofilm formation. The BIOF–HILO assay and MALDI–TOF
MS-based identification assay are substantially similar when
comparing isolates’ spectra. However, we did not employ any
reference database of C. parapsilosis mass spectra for comparison
purposes in this assay.
MATERIALS AND METHODS
Study Organisms
Fifty C. parapsilosis sensu stricto (hereafter referred to as
C. parapsilosis) isolates collected from single patient candidemia
episodes at the Fondazione Policlinico Universitario Agostino
Gemelli IRCCS in Rome, Italy, were included in the study. The
institutional Ethics Committee approved the study (no. 1401/16).
No informed consent from patients was requested because testing
was performed only on anonymized frozen isolates. These isolates
had been characterized as high (n = 25) or low (n = 25) biofilm
producers, i.e., as HP or LP, respectively, using the crystal-violet
binding assay (Soldini et al., 2018). Isolates grew as biofilms
in 96-well microtiter plates at 37◦C for 24-h, starting from
a standardized suspension (1 × 106 cells/ml) in RPMI 1640
broth medium (Sigma-Aldrich, St. Louis, MO, United States). As
measured by the crystal violet retention, the optical density at
540 nm (OD540 nm) values were >1.17 for HP isolates and <0.44
for LP isolates, according to the OD540 nm cutoff values (<0.44,
0.44–1.17, and >1.17) used to classify Candida species isolates
as low, moderate, and high biofilm level producers, respectively
(Soldini et al., 2018).
MALDI–TOF MS Assay
Preliminarily, one HP and one LP C. parapsilosis isolate at
different time points (1.5, 3, 4.5, 6, 8, and 24 h) were studied
using biological (i.e., three from repeated cultivations on different
days) and technical (i.e., two from each same cultivation)
isolate replicates, obtained as described below. These experiments
allowed us to find the optimal time at which the differences
between the HP and LP isolates’ mass spectra could be correctly
detected (data not shown).
Upon optimization of the experimental parameters, all the
50 C. parapsilosis isolates were blindly tested with the BIOF–
HILO assay. First, frozen isolate stocks were sub-cultured on
Sabouraud dextrose agar (SDA) plates. Then, the isolates were
grown in yeast extract–peptone–dextrose broth, under agitation
at 150 rpm, overnight at 37◦C. For each isolate, cells were
harvested, washed twice with 0.15 M phosphate-buffered saline
(PBS; pH 7.2, Ca2+- and Mg2+-free), and were used to obtain
a 2-McFarland suspension (equivalent to ∼0.5 × 107 cells/ml)
in RPMI 1640 broth. After 3-h incubation in a 24-well cell
culture plate, both the suspended (i.e., harvested by taking all
the supernatant) and attached (i.e., harvested by scraping the
well after addition of 200 µl of water) cells from each well were
collected in two separate Eppendorf tubes, centrifuged, and twice
washed in water. Randomly, a 0.1-ml aliquot of C. parapsilosis
cells was plated in triplicate onto SDA and, then, the plates were
read after 24-h incubation at 37◦C for the CFU/ml determination.
Expectedly, the number of cells attached to the microplate wells
after 3-h was substantially higher than the number of cells
suspended (i.e., non-attached) in HP isolates rather than in LP
isolates (data not shown).
For MALDI–TOF MS analysis, the protein cell content was
extracted from the 50 C. parapsilosis isolates, according to
the fast formic-acid protocol previously developed (De Carolis
et al., 2014b). The RNase B solution (1 mg/ml; Sigma-Aldrich,
Milan, Italy) was used as an internal standard, which was added
to each sample before MALDI–TOF mass spectra acquisition.
Samples were spotted in duplicate on a MALDI polished target
plate and measurements were performed with an MBT Smart
mass spectrometer (Bruker Daltonics, Bremen, Germany) after
calibration with a Bacterial Test Standard (Bruker Daltonics). The
α-cyano-4-hydroxycinnamic acid (HCCA) matrix was used for
sample crystallization. Spectra for each sample were generated
from 500 laser shots acquired in automatic mode (100 laser
shots at five different spot positions), and analyzed in a 3000–
7000 Da range by dividing each spectrum into four intervals of
the same size through the CCI tool of the MALDI BiotyperTM
system (Bruker Daltonics). The mass spectra obtained from each
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FIGURE 1 | A CCI matrix based visualization for two representative isolates of HP (A) and LP (B) C. parapsilosis. Reddish colors indicate a close relationship
between the isolates’ mass spectrum profiles. The CCI values refer to the suspended or attached cell profiles matched against the RNase-B internal standard’s
profile, respectively. The right picture shows the row spectra profiles of the internal standard and the suspended or attached isolates’ cells used to create the CCI
matrix.
FIGURE 2 | Categorization of the 50 C. parapsilosis isolates (25 HP and 25 LP) included in the study based on the CCIsusp/CCIattach ratio (for details, see
Supplementary Table S1). Bars indicate the minimum and maximum CCI ratio obtained for each of the three biological replicates of each isolate, with the mean
value marked as a dark dot. According to the discriminatory power of the BIOF–HILO assay, the HP and LP isolates settled in the upper or the lower part of the plot,
respectively.
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isolate’s suspended or attached cells and from the RNase B alone
were compared with each other using the MALDI Biotyper 3.1
software by the CCI analysis (De Carolis et al., 2012), and were
automatically visualized in a CCI matrix view.
Organism Categorization
For comparison analysis, the MALDI–TOF mass spectrum
profiles of the suspended or attached cells from each isolate’s
biological replicates were matched against the internal standard’s
mass spectrum (unpaired t test; p < 0.05). Then, each isolate
was categorized as HP or LP if the CCI obtained by matching
the internal standard’s profile vs. the suspended cells’ profile
(CCIsusp) was higher (i.e., in the case of HP) or lower (i.e.,
in the case of LP) than the CCI obtained by matching the
internal standard’s profile vs. the attached cells’ profile (CCIattach),
respectively. To take variation in the spectral profiles between
HP and LP isolates into account CCI ratios were used, which
were obtained by dividing the CCIsusp by the CCIattach (see
Supplementary Table S1). Accordingly, an isolate was defined as
HP if the CCIsusp/CCIattach ratio was higher than one or as LP
if the CCIsusp/CCIattach ratio was lower than one. Results were
visualized as scatter plots using GraphPad Prism version 8.0.0
(GraphPad Software, Inc., La Jolla, CA, United States).
RESULTS AND DISCUSSION
Figures 1, 2 show the BIOF–HILO assay to discriminate between
HP and LP C. parapsilosis isolates. Specifically, Figure 2 illustrates
that the BIOF–HILO assay discriminated all clinical isolates
(n = 50) within 3-h in line with the biofilm levels (high or
low) as previously established by Soldini et al. (2018) (see also
Supplementary Table S1). Figure 3 shows a comprehensive
representation (from the sample to the result) of the BIOF–
HILO assay. Based on our findings, BIOF–HILO assay, testing
adhesions after 3-h, provides a substitute for the test after 24-h
to measure the biofilm formed by clinical C. parapsilosis isolates.
Consistent with our data, Pannanusorn et al. (2014) showed in
an in vitro study that the initial adhesion to plastic surfaces
(e.g., plate wells) after 3-h correlates with the different biofilm
phenotypes displayed by clinical C. parapsilosis isolates, which in
turn reflect their capacity to form high or low biofilm.
Our findings provide further insights into the clinical
diagnostic possibilities of MALDI–TOF MS shown for
Candida species (including C. parapsilosis). These possibilities
encompass the in vitro assays for fungal identification,
susceptibility/resistance detection, and typing, particularly
for emerging Candida species (De Carolis et al., 2014a; Dhieb
et al., 2015; Vella et al., 2017; Bao et al., 2018; Paul et al.,
2018; Vatanshenassan et al., 2018, 2019). Very few studies, to
date, tempted to apply the MALDI–TOF MS technology to
the direct detection of biofilm-forming isolates of Candida
species. Kubesová et al. (2012) used MALDI–TOF MS with
intact cells and with sinapinic acid as a MALDI matrix to
distinguish rapidly and reliably between two biofilm-negative
and two biofilm-positive strains of C. parapsilosis (and Candida
metapsilosis). Mlynáriková et al. (2016) used MALDI–TOF MS
FIGURE 3 | The BIOF–HILO assay workflow.
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with ethanol/formic-acid extracted cells to differentiate between
12 biofilm-positive and 9 biofilm-negative C. parapsilosis strains
using different MALDI matrices (HCCA, ferulic acid, etc.)
and experimental conditions (cultivation times or media).
However, the authors failed to group reliably the strains
in two clusters within a MALDI–TOF mass spectra-based
dendrogram, because mass spectra variations seemed to limit the
reproducibility of the method.
We focused on the early development phase of the
C. parapsilosis biofilm with MALDI–TOF MS analysis.
Furthermore, we employed an automated CCI matrix-based
algorithm facilitating the relatedness analysis between the mass
spectra from HP or LP C. parapsilosis isolates. This algorithm
allowed us to interpret objectively the MALDI–TOF MS analysis
results and to achieve a reliable separation between the mass
spectra profiles derived from experimental samples such as
the attached or suspended cells of C. parapsilosis isolates, as a
fingerprint matching technique previously described (De Carolis
et al., 2012). We assessed the extent of this separation between the
mass spectra of HP or LP C. parapsilosis isolates by quantifying
their differences in mass peaks with respect to the RNase-B
internal standard. In this context, we chose a molecular mass
range analysis of 3000–7000 Da, which excluded the portion of
the mass spectrum profile where only RNase-B mass peaks are
detectable but allowed to assess the isolates’ mass peaks within
the lower range.
MALDI–TOF MS assays are helpful to identify directly
microbial organisms from clinical samples (Rodríguez-Sánchez
et al., 2019). However, at least for Candida organisms, growing
the isolates before the spectral profiles MALDI–TOF MS
analysis is still a fundamental step when testing isolates
for their capability of biofilm formation. Our assay seems
to be particularly promising as it offers the possibility to
combine MALDI–TOF MS-based identification with biofilm
formation testing. In the latter case, only a short-incubation
is required prior to testing; this, coupled with an unbiased
capability of classifying the isolates, implies the assay to be
advantageous compared with the conventional (Sanguinetti
and Posteraro, 2016) or previously developed MALDI–TOF
MS-based (Mlynáriková et al., 2016) biofilm detection assays.
The rapid and inexpensive protein spectra acquisition using
MALDI–TOF MS has led the technology to a standard tool in
clinical settings. Currently, MALDI–TOF MS allows obtaining
reliable identification and antimicrobial susceptibility testing
results for the microbial pathogens within one working shift
(Rodríguez-Sánchez et al., 2019). As these results are crucial for
timely administration of effective antimicrobial treatment, the
simultaneous additional information on the status of biofilm
formation by pathogens in a quick manner may therefore
enhance the likelihood that the administered antimicrobial
treatment will be efficacious.
In conclusion, we ideated the BIOF–HILO assay with the
purpose to provide a more rapid identification of C. parapsilosis
isolates with high or low capacity of biofilm formation compared
to the methods currently used in the clinical mycology laboratory
(Sanguinetti and Posteraro, 2016). However, further studies using
a larger number of C. parapsilosis isolates are needed, which can
validate the present findings and additionally establish whether
the BIOF–HILO assay may have in the near future a place in
laboratory diagnostics.
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